Yahoo · Sep 29, 2026
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
GOOGL, MA and ABBV headline today's research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.
IC
NASDAQ · ICCC
ImmuCell Corporation
Healthcare · Biotechnology
$9.80
Up+$0.05 (+0.51%)
Updated Oct 10, 2026, 4:30 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 54.28M
- P/E ratio
- 23.36
- Dividend yield
- 0.00%
- 52-week range
- $6.00 – $12.10
- Volume
- 1.86K
- Avg. volume
- 18.99K
Price performance · ICCC
ICCC price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ICCC closed at $9.80 after 21 trading sessions, down 0.51% for the selected period.
- Last close
- $9.80
- Period change
- -0.51%
- Period low
- $9.58
- Period high
- $10.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $9.75 | $9.80 | $9.65 | $9.80 | 1.86K |
| Oct 8, 2026 | $9.74 | $9.85 | $9.6501 | $9.75 | 5.1K |
| Oct 7, 2026 | $9.96 | $9.9871 | $9.69 | $9.69 | 5.16K |
| Oct 6, 2026 | $9.9309 | $9.97 | $9.9309 | $9.97 | 832.11 |
| Oct 5, 2026 | $9.75 | $9.80 | $9.67 | $9.75 | 11.26K |
| Oct 2, 2026 | $9.80 | $9.80 | $9.61 | $9.75 | 5.81K |
| Oct 1, 2026 | $9.80 | $9.80 | $9.551 | $9.60 | 39.53K |
| Sep 30, 2026 | $9.8846 | $9.90 | $9.735 | $9.80 | 2.55K |
| Sep 29, 2026 | $9.92 | $10.10 | $9.92 | $9.94 | 2.94K |
| Sep 28, 2026 | $9.78 | $10.11 | $9.69 | $9.88 | 4.45K |
| Sep 25, 2026 | $9.96 | $9.96 | $9.6701 | $9.925 | 5.05K |
| Sep 24, 2026 | $9.96 | $10.082 | $9.96 | $9.97 | 2.13K |
| Sep 23, 2026 | $10.03 | $10.07 | $9.85 | $9.99 | 7.87K |
| Sep 22, 2026 | $10.10 | $10.10 | $9.805 | $9.99 | 36.07K |
| Sep 21, 2026 | $9.80 | $10.16 | $9.74 | $10.13 | 3.18K |
| Sep 18, 2026 | $9.80 | $9.99 | $9.68 | $9.95 | 10.04K |
| Sep 17, 2026 | $9.615 | $9.98 | $9.56 | $9.98 | 32.94K |
| Sep 16, 2026 | $9.63 | $9.85 | $9.46 | $9.61 | 32.14K |
| Sep 15, 2026 | $9.75 | $9.8399 | $9.50 | $9.58 | 20.89K |
| Sep 14, 2026 | $9.80 | $9.85 | $9.71 | $9.71 | 14.82K |
| Sep 11, 2026 | $9.91 | $9.91 | $9.6341 | $9.85 | 8.1K |
Latest ICCC news
The latest Smart Investors Daily articles mentioning ICCC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ICCC research
Overview
Company profile and research snapshot.
Company profile
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 28, 2026
Top Research Reports for Alphabet, Mastercard & AbbVie
Alphabet's AI-led cycle is strengthening Search, Cloud and subscriptions, while rising investment and regulatory risks create uncertainty around returns.
SeekingAlpha · Aug 14, 2026
ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-08-14. The following slide deck was published by ImmuCell Corporation in conjunction with their 2026 Q2 earnings call.
SeekingAlpha · Aug 14, 2026
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
